12,554 Shares in Astrazeneca Plc $AZN Bought by Burling Wealth Partners LLC

Burling Wealth Partners LLC acquired a new stake in Astrazeneca Plc (NYSE:AZN) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,554 shares of the company’s stock, valued at approximately $2,476,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Triumph Capital Management acquired a new position in Astrazeneca during the 3rd quarter worth about $25,000. MV Capital Management Inc. bought a new stake in shares of Astrazeneca in the 4th quarter valued at about $26,000. Mascoma Wealth Management LLC acquired a new stake in shares of Astrazeneca in the first quarter valued at about $26,000. Bangor Savings Bank increased its stake in shares of Astrazeneca by 102.7% in the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after buying an additional 154 shares during the period. Finally, Eagle Bay Advisors LLC bought a new position in shares of Astrazeneca during the fourth quarter worth about $30,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently commented on AZN. Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. Bank of America restated a “buy” rating on shares of Astrazeneca in a report on Wednesday, July 1st. Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a research report on Friday, June 26th. Weiss Ratings lowered shares of Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 18th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Astrazeneca has a consensus rating of “Moderate Buy” and a consensus price target of $211.00.

Astrazeneca Stock Down 2.8%

Shares of NYSE:AZN opened at $164.14 on Tuesday. The company has a market capitalization of $254.56 billion, a price-to-earnings ratio of 24.65, a P/E/G ratio of 1.38 and a beta of 0.24. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The business’s 50-day moving average is $181.80 and its 200-day moving average is $188.30. Astrazeneca Plc has a 1 year low of $137.23 and a 1 year high of $212.71.

Astrazeneca (NYSE:AZN) last released its earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The business had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Equities research analysts predict that Astrazeneca Plc will post 10.22 earnings per share for the current year.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.